Expression levels of toll-like receptor genes in coronary athe...

Collect this paper and discover other ones on Labmeeting. Learn more.
- Hide Abstract
Background: The differences between acute coronary syndrome (ACS) and stable angina pectoris (SAP) in Toll-like receptor (TLR) expression levels in coronary plaques are not well known. TLR gene expression levels were examined, not only in peripheral blood mononuclear cells (PBMCs), but also in coronary plaques in ACS and SAP patients. Methods and Results: TLR gene expression levels were examined in PBMCs using real-time RT-PCR in 27 ACS patients, 45 SAP patients and 28 control subjects. TLR2 and TLR4 expression levels in the PBMCs were significantly higher in the ACS group than in the SAP group. TLR9 expression levels were not significantly different among the 3 groups. TLR gene expression levels were also measured in directional coronary atherectomy (DCA) samples from 9 ACS and 14 SAP patients. The TLR2 expression levels in the DCA samples did not significantly differ between the 2 groups. The TLR4 expression levels were significantly higher in the ACS group than in the SAP group. Conclusions: The results suggest that TLR4 signaling could be more associated with plaque destabilization than with plaque progression. TLR4 expression control may be a novel target for ACS treatment. (Circ J 2009; 73: 1479 - 1484).
Circulation journal : official journal of the Japanese Circulation Society 73(8):1479-84, 2009 AugWho cited this? | PubMed ID: 19556696 | Fulltext


+ Click Here for Related Papers


Join Labmeeting

  • Organize and search your PDF collection
  • Collect papers
  • Search millions of papers
  • Keep up to date with paper alerts
  • Read your papers from anywhere
  • Recommend papers to colleagues
  • Manage your lab

Join Labmeeting

Labmeeting is a web service for researchers. Sign up with your academic email address.

Individuals or corporations not affiliated with an academic institution can request a trial subscription.


Got a question?
The Labmeeting Network
has the answer.
Ask scientists at top universities like Harvard, Stanford, and MIT for their expert opinion!